European Drugmakers Delay New Medicine Launches Over Pricing Pressure
Global Health Headlines: Drugs, Vaccines, and Policies in Focus | Health
Drugmakers in Europe are holding back the introduction of new medicines due to price policy changes under pressure from the US administration This move follows President Donald Trumps efforts to tie US drug costs to prices in other countries a strategy known as most-favored-nation pricing
European pharmaceutical companies are postponing new drug introductions amid stricter price policies influenced by US administration pressure. President Trump's most-favored-nation pricing strategy, which ties US drug costs to international prices, has prompted drugmakers to reconsider their market expansion timelines. The policy shift could delay patient access to innovative treatments across Europe.
Original Article
Read full article on DevdiscourseExplore More
Related News
Knox Public Health celebrates National Public Health Week
2026.04.05
World Health Day 2026: The Invisible Crisis Could Be Sabotaging Your Health
Free Press Journal · 2026.04.05
Health rules under review
The Star | Malaysia News: National, Regional and World News · 2026.04.05
Opinion: Health care delayed, health care denied
Winnipeg Free Press – Breaking News, Sports, Manitoba, Canada · 2026.04.04
OpenLoop Health has acquired nutrition startup Season Health
2026.04.04
St. Vincent Behavioral Health Campus Expands Housing & Health Care for LA with $6M Health Net Investment
PR Newswire: press release distribution, targeting, monitoring and marketing · 2026.04.04